Maegim한국어

휴젤

145020KOSDAQSector: Pharma & Biotech
₩228,500▼ 0.65%Market cap ₩2.81TAs of Jul 21, 2026 close · updated once daily
A
Grade A72.9 ptsTop 7% of 2,523 stocks
Financial strength
90.2
Growth momentum
73.1
Price attractiveness
52.9

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

90.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
9.9%
✓ Above median · Top 12% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
730.1%
✓ Above median · Top 19.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
47.2%
✓ Above median · Top 1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
14.8%
✓ Above median · Top 6.7% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

73.1
How much did revenue grow in a year?
Revenue growth (YoY)
14.0%
✓ Above median · Top 32.2% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
14.7%
✓ Above median · Top 20.6% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
20.8%
✓ Above median · Top 36.4% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
98.1%
✓ Above median · Top 18.5% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

52.9
Is the price expensive relative to earnings?
P/E (price-to-earnings)
20.0x
✓ Above median · Top 24.6% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
2.96x
✗ Below median · Top 69.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15